Paasa Logo
InMed Pharmaceuticals Inc. logo
INMNASDAQMarket closedOpens 9:30am ET

InMed Pharmaceuticals Inc.

$1.38Last updated
+$0.02 (1.10%)Past day
Timezone

InMed Pharmaceuticals Inc. (NASDAQ: INM) is trading at $1.38, about ₹132 at today's USD/INR rate, as of 29 Sep 2026, 4:00 PM ET, up 1.10% today. Indian residents can buy InMed Pharmaceuticals from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$1.34
Previous close:$1.36
Volume:60.53K

Today's low

$1.34

Today's high

$1.41

52 week low

$0.58

52 week high

$2.50

INM opened at $1.34, closed previously at $1.36, and has traded between $0.58 and $2.50 over the past 52 weeks.

About

InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.

Country
CA
CEO
Eric A. Adams Chem.
Exchange listed on
NASDAQ
Industry
Drug Manufacturers - Specialty & Generic
Base currency
USD
Full Time Employees
6
Sector
Healthcare
IPO date
05/05/2014

Key statistics

Avg. volume

745.58K

Market cap

$7.55M

P/E Ratio

-0.39

Price-to-sales ratio

0.00

Enterprise value

$4.26M

Free cash flow yield

-133933.68%

Debt-to-equity ratio

0.00

Return on equity

-1168.44%

ROIC

-920.47%

Beta

0.98

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

$3.18B

Earnings per share

-$3.12

Free cash flow

-$8.64B

Net profit margin

-0.61%

Gross margin

14.92%

EBITDA

-$9.19M

Revenue growth

64167.28%

Similar securities

This is not an investment recommendation

How to buy InMed Pharmaceuticals from India

Indian residents can buy InMed Pharmaceuticals shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for InMed Pharmaceuticals and place an order

    Find InMed Pharmaceuticals by name or by its ticker, INM, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. InMed Pharmaceuticals trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your InMed Pharmaceuticals position in USD and INR. InMed Pharmaceuticals pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in InMed Pharmaceuticals from India

Trading and taxes when buying InMed Pharmaceuticals from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneInMed Pharmaceuticals does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy InMed Pharmaceuticals stock?

Yes. InMed Pharmaceuticals (INM) has been listed on NASDAQ since 2014, in the Drug Manufacturers - Specialty & Generic industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one InMed Pharmaceuticals share cost in rupees?

One InMed Pharmaceuticals share is $1.38 — about ₹132 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the InMed Pharmaceuticals price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying InMed Pharmaceuticals from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy whole shares of InMed Pharmaceuticals?

Yes. One InMed Pharmaceuticals share is $1.38, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in InMed Pharmaceuticals.

How are gains on InMed Pharmaceuticals shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the InMed Pharmaceuticals price. Paasa issues a capital-gains statement for your return.

Does InMed Pharmaceuticals pay a dividend?

No. InMed Pharmaceuticals does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade InMed Pharmaceuticals from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is InMed Pharmaceuticals a United States company, and does that change how it is taxed?

InMed Pharmaceuticals trades on NASDAQ in US dollars, but the company is domiciled in Canada. InMed Pharmaceuticals trades as an ordinary share listed directly in the US, not a depositary receipt. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Your India-side capital-gains treatment is the same either way.

Do I have to declare InMed Pharmaceuticals shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your InMed Pharmaceuticals holding, its cost and its closing value.

How do I sell InMed Pharmaceuticals and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.